TG2 Identified As Potential Therapeutic Target In Chemo-resistant Ovarian Cancer

Researchers connect overexpression of tissue type transglutaminase with poor prognosis in ovarian cancer, identify the relevant pathway, and shut TG2 down with an siRNA liposomal nanoparticle. They previously pinpointed TG2's role in resistant and metastatic melanoma and breast and pancreatic cancers. This crucial protein fuels different cancers through different pathways.

Read the whole article on Science Daily

More from Science Daily